Last reviewed · How we verify

Donor Fecal Microbiota Transplantation

Madhusudan (Madhu) Grover, MBBS · Phase 2 active Biologic Quality 15/100

Donor Fecal Microbiota Transplantation is a Biologic drug developed by Madhusudan (Madhu) Grover, MBBS. It is currently in Phase 2 development.

At a glance

Generic nameDonor Fecal Microbiota Transplantation
SponsorMadhusudan (Madhu) Grover, MBBS
ModalityBiologic
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Donor Fecal Microbiota Transplantation

What is Donor Fecal Microbiota Transplantation?

Donor Fecal Microbiota Transplantation is a Biologic drug developed by Madhusudan (Madhu) Grover, MBBS.

Who makes Donor Fecal Microbiota Transplantation?

Donor Fecal Microbiota Transplantation is developed by Madhusudan (Madhu) Grover, MBBS (see full Madhusudan (Madhu) Grover, MBBS pipeline at /company/madhusudan-madhu-grover-mbbs).

What development phase is Donor Fecal Microbiota Transplantation in?

Donor Fecal Microbiota Transplantation is in Phase 2.

What are the side effects of Donor Fecal Microbiota Transplantation?

Common side effects of Donor Fecal Microbiota Transplantation include Diarrhoea, Abdominal pain, Defaecation urgency, Nausea, Abdominal distension, Decreased appetite.

Related